Literature DB >> 9130591

A unique cathepsin-like protease isolated from CV-1 cells is involved in rapid degradation of retinoblastoma susceptibility gene product, RB, and transcription factor SP1.

T Nishinaka1, Y H Fu, L I Chen, K Yokoyama, R Chiu.   

Abstract

The regulation of transcription factors by kinase or phosphatase has been well-described. However, little is known about the inactivation of transcription factors or the nuclear regulators by proteolytic degradation. In this report, we purified a specific protease, SPase, from nuclear extracts of the green monkey kidney cell line, CV-1. Studies of biochemical characteristics and substrate specificity indicated that SPase is a cathepsin B-like cysteinyl protease. However, the two tryptic peptide sequences derived from the purified SPase are either identical or highly homologous to those of human cathepsin L, and furthermore, SPase shares immunoreactivity with both anti-human cathepsin L and anti-mouse cathepsin L antibody. The SPase was shown to be localized in both cytoplasm and nucleus when subcellular compartments of CV-1 cells were fractionated. Transcription factor, SP1, and retinoblastoma susceptible gene product, RB, are substrates of SPase while other nuclear factors such as c-Jun and c-Fos are not. These results implied that SPase plays an integral role in regulating a set of proteins in the nuclei. In vivo treatment of CV-1 cells with cysteinyl protease inhibitor, E-64d, protected RB from degradation. SPase failed to degrade underphosphorylated RB present in TPA induced terminally differentiated HL-60 or U937 cells. Phosphorylation of RB may cause conformational changes, thus facilitating proteolytic digestion. These observations suggest that an alternative pathway inactivates the function of RB in controlling cell growth. Therefore, a possible role of SPase may be to affect the stability of important regulators involved in controlling cellular proliferation and differentiation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9130591     DOI: 10.1016/s0167-4781(96)00210-2

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

1.  pRB induces Sp1 activity by relieving inhibition mediated by MDM2.

Authors:  T Johnson-Pais; C Degnin; M J Thayer
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

2.  Nuclear localization of catalytically active MMP-2 in endothelial cells and neurons.

Authors:  Satyesh K Sinha; Kamlesh Asotra; Hiroyasu Uzui; Santosh Nagwani; Vivek Mishra; Tripathi B Rajavashisth
Journal:  Am J Transl Res       Date:  2014-01-15       Impact factor: 4.060

3.  Regulation of Sp1 by cell cycle related proteins.

Authors:  Alicia Tapias; Carlos J Ciudad; Igor B Roninson; Véronique Noé
Journal:  Cell Cycle       Date:  2008-09-24       Impact factor: 4.534

4.  The Sp1 family of transcription factors is involved in p27(Kip1)-mediated activation of myelin basic protein gene expression.

Authors:  Qiou Wei; W Keith Miskimins; Robin Miskimins
Journal:  Mol Cell Biol       Date:  2003-06       Impact factor: 4.272

5.  Processing of capsid protein by cathepsin L plays a crucial role in replication of Japanese encephalitis virus in neural and macrophage cells.

Authors:  Yoshio Mori; Tetsuo Yamashita; Yoshinori Tanaka; Yoshimi Tsuda; Takayuki Abe; Kohji Moriishi; Yoshiharu Matsuura
Journal:  J Virol       Date:  2007-06-06       Impact factor: 5.103

6.  Effects of altered expression and localization of cyclophilin A on differentiation of p19 embryonic carcinoma cells.

Authors:  Robert Chiu; Osvaldo Rey; Jun-Qi Zheng; Jeffery L Twiss; Jun Song; Shen Pang; Kazunari K Yokoyama
Journal:  Cell Mol Neurobiol       Date:  2003-12       Impact factor: 5.046

7.  Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor.

Authors:  KyungWon Huh; Xiaobo Zhou; Hiroyuki Hayakawa; Je-Yoel Cho; Towia A Libermann; Jianping Jin; J Wade Harper; Karl Munger
Journal:  J Virol       Date:  2007-07-03       Impact factor: 5.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.